BEAM
Beam Therapeutics Inc. · Healthcare
25.44
3.88%(+0.95)
Prev. Close25.69
0.98%(+0.25)
Pre-marketLast Updated: — ET
52W L: $13.5452W H: $36.44
Beam Therapeutics Inc. · Healthcare
Evans John M.
director, officer: CEO
30,078 SH @ $24.58
2026-04-01
Simon Amy
officer: Chief Medical Officer
6,700 SH @ $24.58
2026-04-01
Cavanagh Bethany J
officer: SVP, Finance and Treasurer
3,242 SH @ $24.58
2026-04-01
Bellon Christine
officer: Chief Legal Officer
5,956 SH @ $24.58
2026-04-01
Ciaramella Giuseppe
officer: President
11,810 SH @ $24.58
2026-04-01
Bellon Christine
officer: Chief Legal Officer
20,000 SH @ $0.00
2026-03-31
Cavanagh Bethany J
officer: SVP, Finance and Treasurer
20,000 SH @ $0.00
2026-03-31
Simon Amy
officer: Chief Medical Officer
31,750 SH @ $0.00
2026-03-31
Beam Therapeutics Inc. (NASDAQ: BEAM - Get Free Report) insider Amy Simon sold 6,700 shares of the business's stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $24.58, for a total transaction of $164,686.00. Following the transaction, the insider directly owned 102,735 shares of the company's stock, valued
Beam Therapeutics Inc. (NASDAQ: BEAM - Get Free Report) insider Christine Bellon sold 5,956 shares of Beam Therapeutics stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $24.58, for a total value of $146,398.48. Following the sale, the insider owned 109,711 shares in the company, valued at $2,696,696.38.
Beam Therapeutics Inc. (NASDAQ: BEAM - Get Free Report) President Giuseppe Ciaramella sold 11,810 shares of the company's stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $24.58, for a total transaction of $290,289.80. Following the completion of the transaction, the president owned 218,406 shares in
SG Americas Securities LLC lifted its stake in shares of Beam Therapeutics Inc. (NASDAQ: BEAM) by 139.4% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 103,469 shares of the company's stock after buying an additional 60,249 shares during the
Prestigious Publication Reinforces risto-cel's Durable, Differentiated Clinical Data for the Treatment of SCD with Severe Vaso-occlusive Crises (VOCs)
Beam Therapeutics (NASDAQ: BEAM) executives and clinical collaborators presented updated top-line data from the company's ongoing Phase I/II study of BEAM-302, an in vivo base-editing therapy being evaluated in patients with alpha-1 antitrypsin deficiency (AATD). The call focused on efficacy and safety results from 29 treated patients as of a February 10, 2026 data cutoff, along